

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 January 2025 (16.01.2025)



(10) International Publication Number
WO 2025/012812 A1

(51) International Patent Classification:

A61K 51/04 (2006.01) A61K 103/30 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2024/056674

(22) International Filing Date:

09 July 2024 (09.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/512,925 11 July 2023 (11.07.2023) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **CARBINI, Mariana**; Novartis Pharma AG,
Lichtstrasse 35, 4056 Basel (CH). **ILANKUMARAN,
Palanichamy**; Novartis Pharmaceuticals Corporation, 59
Route 10, East Hanover, New Jersey 07936 (US). **SAR-
TOR, Alton Oliver**; 922 Esplanade Avenue, New Orleans,
Louisiana 70116 (US). **WILKE, Celine Christiana Anna**;
Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: METHOD OF TREATING PROSTATE CANCER

(57) Abstract: The present disclosure relates to a method of treating prostate-specific membrane antigen (PSMA)-positive oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor comprising the administration of a therapeutically effective amount of a PSMA-binding radioligand therapeutic (RLT) agent, preferably [¹⁷⁷Lu]Lu-PSMA-617 (lutetium (¹⁷⁷Lu) vipivotide tetraxetan). Further, the present disclosure relates to radioligand therapy of early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).



WO 2025/012812 A1